Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

551
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
551
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

474
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
474
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

673
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
673
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

428
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
428
Ventilatory Modes01:14

Ventilatory Modes

1.8K
Mechanical ventilators are life-saving devices that support or replace spontaneous breathing. They deliver breaths to patients through varying methods known as ventilator modes. Understanding these modes is critical for healthcare providers managing patients with respiratory failure.
There are three ventilatory modes: full support, partial support, and spontaneous. These are described below.
Full Support Modes
Full support modes include controlled mechanical ventilation, continuous mandatory...
1.8K
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

376
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
376

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ironing Out the Details: Advancing Diagnosis and Treatment of Iron Deficiency in Patients with Heart Failure with Preserved Ejection Fraction - A Narrative Review.

Heart failure reviews·2026
Same author

JCF In Case You Missed It! Summary of American College of Cardiology (ACC) 2026.

Journal of cardiac failure·2026
Same author

Reflections from the Other Side of the Bed, Part 2.

Journal of cardiac failure·2026
Same author

Ambulatory Stage C2D Heart Failure Definitions and Current Therapeutic Approaches: JACC: Heart Failure Position Statement.

JACC. Heart failure·2026
Same author

Early-Onset Vitreous and Cardiac Amyloidosis With TTR Trp61Leu.

JACC. Case reports·2026
Same author

Safety and Feasibility of the eLymTM System for Interstitial Decongestion in Acute Decompensated Heart Failure: Primary results of the DELTA-HF trial.

European journal of heart failure·2026

Related Experiment Video

Updated: Mar 1, 2026

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

10.0K

Left Ventricular Assist Devices for Lifelong Support.

Sean P Pinney1, Anelechi C Anyanwu2, Anuradha Lala1

  • 1Zena and Michael Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.

Journal of the American College of Cardiology
|June 10, 2017
PubMed
Summary

Continuous-flow left ventricular assist devices (LVADs) improve survival and quality of life for advanced heart failure patients. Further advancements are needed to ensure long-term efficacy, reduce adverse events, and improve cost-effectiveness for widespread adoption.

Keywords:
cardiothoracic surgeryheart failurehemocompatibility

More Related Videos

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

4.2K
Implantation of Left Ventricular Assist Device (LVAD) in Juvenile Landrace Swine: A LVAD Implantation Model of Pediatric Heart Failure
05:18

Implantation of Left Ventricular Assist Device (LVAD) in Juvenile Landrace Swine: A LVAD Implantation Model of Pediatric Heart Failure

Published on: January 16, 2026

97

Related Experiment Videos

Last Updated: Mar 1, 2026

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

10.0K
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

4.2K
Implantation of Left Ventricular Assist Device (LVAD) in Juvenile Landrace Swine: A LVAD Implantation Model of Pediatric Heart Failure
05:18

Implantation of Left Ventricular Assist Device (LVAD) in Juvenile Landrace Swine: A LVAD Implantation Model of Pediatric Heart Failure

Published on: January 16, 2026

97

Area of Science:

  • Cardiovascular Medicine
  • Biomedical Engineering
  • Heart Failure Management

Background:

  • Continuous-flow left ventricular assist devices (LVADs) represent a significant advancement in treating advanced heart failure.
  • These fully implantable pumps enhance survival, functional capacity, and quality of life for patients.
  • Growing implantation volumes highlight the increasing reliance on LVADs.

Purpose of the Study:

  • To review engineering, implantation, and medical management advancements in LVADs.
  • To identify progress toward achieving lifelong support with LVADs.
  • To outline remaining challenges for LVAD therapy.

Main Methods:

  • Review of current literature on LVAD technology and clinical outcomes.
  • Analysis of engineering design principles aimed at reducing adverse events.
  • Examination of medical management strategies for optimizing LVAD patient care.

Main Results:

  • LVADs currently offer midterm survival benefits (3-5 years).
  • Key challenges include achieving long-term survival (7-10 years) and reducing adverse events like bleeding, stroke, and pump thrombosis.
  • Reducing device-related shear stress and stasis are critical design considerations.

Conclusions:

  • Significant progress has been made in LVAD technology and patient management.
  • Further innovation is required to overcome current limitations and establish LVADs as a lifelong therapy.
  • Enhancing cost-effectiveness is crucial for broader accessibility and adoption in advanced heart failure care.